BioHarvest Sciences Inc. announced on May 12, 2025, that its Contract Development and Manufacturing Organization (CDMO) contract with a Nasdaq-listed pharmaceutical company has successfully progressed from Stage 1 to Stage 2. This project, initiated in early 2024, aims to develop a compound used in an approved drug product.
Stage 1 involved successfully isolating, mirroring, magnifying, and multiplying the target plant cells in petri dishes using BioHarvest's proprietary Botanical Synthesis platform. This stage carried the highest technical risk, and its completion validates the platform's versatility for pharmaceutical applications.
Stage 2 will focus on delivering a sufficient amount of biomass for testing and optimizing growing conditions in liquid media. This is a crucial step towards small- and medium-scale production, with the potential to eventually reach commercial manufacturing volumes for the target compound.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.